Last reviewed · How we verify
QLS32015
QLS32015 is a small molecule drug that targets the SGLT2 receptor.
QLS32015 is a small molecule drug that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | QLS32015 |
|---|---|
| Also known as | A Humanized GPRC5D x CD3 Bispecific Antibody |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, QLS32015 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of diabetic ketoacidosis
Key clinical trials
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma (PHASE3)
- Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma (PHASE2)
- A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma (EARLY_PHASE1)
- A Study of QLS32015 in Patients With Recurrent or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QLS32015 CI brief — competitive landscape report
- QLS32015 updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI